{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04965688",
            "orgStudyIdInfo": {
                "id": "U21-02-4401"
            },
            "organization": {
                "fullName": "Inova Health Care Services",
                "class": "OTHER"
            },
            "briefTitle": "Systems Biology Guided Therapy for Breast Cancer Positive for Oestrogen Receptor After Aromatase Inhibitor and CDK Inhibition",
            "officialTitle": "Systems Biology Guided Therapy for Breast Cancer Positive for Oestrogen Receptor After Aromatase Inhibitor and CDK Inhibition",
            "acronym": "SPOCK",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "systems-biology-guided-therapy-for-breast-cancer-positive-for-oestrogen-receptor-after-aromatase-inhibitor-and-cdk-inhibition"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-09",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-08-08",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-07",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-07",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-07-07",
            "studyFirstSubmitQcDate": "2021-07-07",
            "studyFirstPostDateStruct": {
                "date": "2021-07-16",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-09-01",
            "lastUpdatePostDateStruct": {
                "date": "2023-09-06",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Inova Health Care Services",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "City of Hope Medical Center",
                    "class": "OTHER"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "There are several approved and guideline-recommended treatments for metastatic, estrogen receptor-positive breast cancer that has progressed on an aromatase inhibitor and a CDK4/6 inhibitor. Right now, doctors do not have a good way of choosing between these treatments. Scientists we work with have come up with ways to use the biology of the tumor to try to predict which treatment is best. This study is being done to test if those predictions are right and to learn more about these tumors to design better treatments in the future."
        },
        "conditionsModule": {
            "conditions": [
                "Breast Cancer",
                "Estrogen Receptor-positive Breast Cancer",
                "HER2-negative Breast Cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "Open label, interventional",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 74,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Drug determined by treating oncologist based on recommendation from systems biology analysis.",
                    "description": "All patients will have a biopsy at the beginning of the trial. The biopsy will be sent for DNA sequencing through FoundationOne(clinical test) and RNA profiling at Fulgent(research test) for determination of activation of various oncogenic pathways and phenotypes. The results will be analyzed and a treatment recommendation will be made to the treating physician based on an algorithm."
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Progression Free Survival",
                    "timeFrame": "24 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Turn around time for systems biology analysis",
                    "timeFrame": "24 months"
                },
                {
                    "measure": "Response rate to systems biology guided therapy",
                    "timeFrame": "24 months"
                },
                {
                    "measure": "Progression free survival base on concordance with recommended treatment",
                    "timeFrame": "24 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologic diagnosis of breast cancer\n* Metastatic or incurable\n* Prior treatment with an anastrozole or letrozole and a CDK4/6 inhibitor\n* Progression while on or within 6 months of stopping the CDK4/6 inhibitor\n* At least one lesion amenable to percutaneous biopsy that is not a purely sclerotic bone lesion\n* ECOG 0-2\n* Age 18 or greater\n* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.\n\nExclusion Criteria:\n\n* Prior treatment within 2 years with fulvestrant, alpelisib, everolimus, or capecitabine\n* Comorbid disease other than breast cancer with a life expectancy of less than 2 years\n* Cancer other than breast cancer that is expected to need treatment within 2 years\n* Platelets \\< 100,000/microliter\n* INR \\> 1.5",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Stephanie Van Bebber, MSc.",
                    "role": "CONTACT",
                    "phone": "571-472-0213",
                    "email": "Stephanie.VanBebber@inova.org"
                },
                {
                    "name": "Keary Janet, BS",
                    "role": "CONTACT",
                    "phone": "571-472-0224",
                    "email": "keary.janet@inova.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Adam Cohen, MD",
                    "affiliation": "Inova Schar Cancer Institute",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Inova Schar Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Stephanie Van Bebber, MSc.",
                            "role": "CONTACT",
                            "phone": "571-472-0213",
                            "email": "Stephanie.VanBebber@inova.org"
                        },
                        {
                            "name": "Keary Janet, BS",
                            "role": "CONTACT",
                            "phone": "571-471-0224",
                            "email": "keary.janet@inova.org"
                        },
                        {
                            "name": "Adam Cohen, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "documentSection": {
        "largeDocumentModule": {
            "largeDocs": [
                {
                    "typeAbbrev": "Prot_ICF",
                    "hasProtocol": true,
                    "hasSap": false,
                    "hasIcf": true,
                    "label": "Study Protocol and Informed Consent Form",
                    "date": "2022-09-18",
                    "uploadDate": "2023-06-21T17:37",
                    "filename": "Prot_ICF_000.pdf",
                    "size": 1667892
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001943",
                    "term": "Breast Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000001941",
                    "term": "Breast Diseases"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "asFound": "Breast Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5218",
                    "name": "Breast Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M8116",
                    "name": "Estrogens",
                    "relevance": "LOW"
                },
                {
                    "id": "M25769",
                    "name": "Aromatase Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}